Current approved options for treating patients with multiple sclerosis

Syed A. Rizvi, Mark A. Agius

Research output: Contribution to journalArticle

76 Scopus citations

Abstract

Multiple sclerosis (MS), a neurologic disorder that affects 400,000 persons in the United States, consists of an inflammatory and a neurodegenerative phase. Treatment options now approved by the FDA specifically target the inflammatory phase of MS and include immunomodulators (i.e., interferon betas and glatiramer acetate) and an immuno-suppressant, mitoxantrone. This article discusses the methods of monitoring disease progression using disability scales and MRI and reviews the clinical efficacy and tolerability of the FDA-approved therapies. All of the immunomodulators are approved for the treatment of relapsing forms of MS, Only mitoxantrone is approved for the treatment of worsening relapsing-remitting MS, secondary progressive MS, and progressive-relapsing MS. Early treatment with these disease-modifying agents is desirable to reduce the progression of the disease and to limit long-term disability.

Original languageEnglish (US)
JournalNeurology
Volume63
Issue number12 SUPPL. 6
StatePublished - Dec 28 2004

ASJC Scopus subject areas

  • Neuroscience(all)

Fingerprint Dive into the research topics of 'Current approved options for treating patients with multiple sclerosis'. Together they form a unique fingerprint.

  • Cite this

    Rizvi, S. A., & Agius, M. A. (2004). Current approved options for treating patients with multiple sclerosis. Neurology, 63(12 SUPPL. 6).